ATM突变转移性去势抵抗性前列腺癌对恩杂鲁胺联合177Lu-PSMA-617放射配体治疗的应答
本文报道一例68岁ATM突变阳性mCRPC患者,在接受恩杂鲁胺与177Lu-PSMA-617同步治疗后出现显著应答。背景指出DNA损伤修复缺陷可能影响前列腺癌放射敏感性,此类患者单用177Lu-PSMA-617可能疗效不佳,需更个体化治疗策略。
要点
- ATM突变mCRPC患者单用177Lu-PSMA-617可能应答不佳。
- 恩杂鲁胺同步联合177Lu-PSMA-617在本例中显示显著应答。
- DNA损伤修复缺陷可能影响前列腺癌放射敏感性。
核心结论
- ATM突变阳性mCRPC患者对恩杂鲁胺同步联合177Lu-PSMA-617治疗出现显著应答。
研究设计与样本
- 本文为单例病例报告,对象为68岁ATM突变阳性mCRPC男性患者。
主要发现
- 该68岁ATM突变阳性mCRPC患者在接受恩杂鲁胺与177Lu-PSMA-617同步给药后显示显著应答。
临床怎么用
- 对携带DNA损伤修复缺陷的mCRPC患者,可考虑恩杂鲁胺同步联合177Lu-PSMA-617的个体化治疗策略。
局限性
- 本文为单例病例报告,不能据此推广至全部ATM突变mCRPC患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioligand therapy with 177Lu-PSMA-617 has emerged as a promising treatment modality for patients with mCRPC (metastatic castration resistant prostate cancer). However, genomic defects in DNA damage repair mechanisms have been proposed to affect the radiosensitivity of prostate cancers. Patients harboring such deleterious mutations are, thus, unlikely to respond to 177Lu-PSMA-617 alone and would need a more tailored therapeutic approach. We report the case of a 68-year-old man with ATM mutation-positive mCRPC who showed exceptional response to concomitant administration of enzalutamide with 177Lu-PSMA-617.
引用
- Satapathy S, Das CK, Parihar AS, et al. Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer. Clin Nucl Med. 2021. PMID: 33630794. doi:10.1097/RLU.0000000000003541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。